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ABSTRACT
Three simple, selective and sensitive methods have been developed and validated for the determination of lamotrigine (LMT)
in pure drug and in tablets. The first method (method A) is based on the formation of ion-pair complex between LMT and the
dye, bromocresol purple (BCP) at pH 2.40 ± 0.01 which was extracted into dichloromethane (DCM) and the absorbance of yellow
ion-pair complex was measured at 410 nm. In the second and third methods (method B and method C), the drug-dye ion-pair was
dissolved either in ethanol and the resulting acid form of the dye was measured at 410 nm or in ethanolic potassium hydroxide
and the resulting base form of the dye was measured at 600 nm. Under the optimized conditions, Beer’s law was obeyed over
2.0-20.0 µg/mL, 150-1500 ng/mL and 50-600 ng/mL for method A, method B and method C, respectively, and the corresponding
molar absorptivity values were 1.018 × 104, 1.43 × 105 and 4.21 × 105 L/mol/cm. The Sandell sensitivity values of 0.0252, 0.0018 and
0.0006 µg/cm 2 for method A, method B and method C, respectively, and the corresponding values for limits of detection and quantification were also reported for all three methods. The molar ratio of the formed ion-pair complex was found to be 1: 1 as deduced by
Job’s method for method A, and the calculated stability constant was also reported. Over the linear ranges applicable, the accuracy
and precision of the methods were evaluated on intra-day and inter-day basis; the reported mean accuracy values are 99.50 ± 1.09%,
99.99 ± 1.11% and 100.72 ± 0.62% for method A, method B, and method C, respectively; the relative error (RE) was ≤ 2.57% and the
relative standard deviation (RSD) was ≤ 2.01%. Application of the proposed methods to bulk powder and commercial pharmaceutical tablets are also presented.
Key words: lamotrigine, bromocresol purple, pharmaceuticals, spectrophotometry, determination

INTRODUCTION
Lamotrigine (LMT), [6-(2,3-dichlorophenyl)-1,2,4triazine-3,5-diamine], is an anticonvulsant drug used in
the treatment of epilepsy and bipolar disorder as monotherapy or as an adjunct with other antiepileptics for
the treatment of partial and generalized toxic-clonic
seizures. It is also used to treat neurological lesions and
as a tranquilizer (1,2). LMT is not official in any pharmacopoeia. Most methods for lamotrigine analysis
utilized HPLC(3-10), HPTLC(11) and GC(12) techniques
in biological fluids. Various analytical techniques that
have been reported for the determination of this drug
in pharmaceuticals include planar chromatography(13),
* Author for correspondence. Tel: +91-821-2419659;
Fax: +91-821-2516133; E-mail: basavaiahk@yahoo.co.in

TLC and HPLC(14), HPLC and GC(15), capillary electrophoresis (16,17) and immunoassay (18). Talekar et al.(19).
have described a UV-spectrophotometric method for the
determination of LMT in tablets where the tablet extract
in 0.1 M sodium hydroxide was measured at 305 nm.
Inspite of its simplicity, fair selectivity and sensitivity,
and reasonable accuracy and precision, visible spectrophotometry has not been utilized for the assay of LMT
except one report (14). Recently Youssef and Taha (14) have
reported the application of the technique for the determination of LMT using chloranilic acid as a chromogen.
The reported method is less sensitive with a linear range
of 10-200 µg/mL and the molar absorptivity of 1.28 × 103
L/mol/cm. Though the method is claimed to be selective,
any N-containing basic moiety would definitely interfere
with the assay.
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Many of the other reported methods are sensitive and
selective but they are time consuming, requires expensive
instrumental setup, and some require preliminary sample
treatment (13-18). Adsorptive stripping voltammetric
method is highly complicated and is reported to be less
precise (RSD ~10%)(20). Considering these drawbacks,
there was a need to develop more advantageous spectrophotometric method for the determination of LMT in bulk
powder and commercial dosage forms.
This paper described three highly sensitive, rapid,
simple, selective and economical spectrophotometric
methods for the determination of LMT in bulk powder
and in tablets by exploiting its basic nature and its ability
to form ion-pair complex with bromocresol purple. The
first method (method A) is based on the formation of an
ion-pair complex between drug and dye bromocresol
purple (BCP) at pH 2.40 ± 0.01 followed by extraction
of the complex into dichloromethane (DCM), and the
absorbance of yellow drug-dye complex was measured
at 410 nm. In the second (method B) and third (method
C) methods, the drug-dye ion-pair was broken either
in ethanol and the resulting acid form of the dye was
measured at 410 nm or in ethanolic alkali and the blue
colour of the base form of the dye was measured at
600 nm. The methods (B and C) offered two highly sensitive approaches for determination of LMT in bulk drug
and in tablets.

MATERIALS AND METHODS
I. Instruments
A Systronic model 106 digital spectrophotometer
(Ahmadabad, India) with matched 1-cm quartz cells was
used for absorbance measurements. A digital pH meter
Model Elico L1 120 was used for pH measurements.

and was used as received. Lamotrigine standard solution
was prepared as 40 µg/mL solution in 0.1 M H 2SO 4 and
used in method A.
III. Recommended Procedures
(I) Method A
Aliquots of LMT standard solution (40 µg/mL)
containing 1-20 µg/mL LMT were transferred into a
series of 125-mL separating funnels and the total volume
was brought to 5 mL by adding 0.1 M H 2SO 4. To each
funnel 15 mL of H 2O, 2 mL of 0.5 M sodium acetate
(NaOAc) and 5 mL of NaOAc-HCl buffer (pH 2.4) were
added. Contents were mixed and 5 mL of 0.25% dye solution was added to each separating funnel, mixed well
and kept aside for 5 min. The drug-dye ion-pair was then
extracted with 10 mL of dichloromethane by shaking
for 30 sec and the layers were allowed to separate. The
organic layer was then passed over anhydrous sodium
sulphate and absorbance was measured at 410 nm against
the reagent blank.
(II) Method B
Into a series of 10-mL volumetric flasks, volumes
of LMT-BCP complex (3 µg/mL, prepared in method A)
equivalent to 150-1500 ng/mL with respect to LMT were
transferred. The total volume in each flask was brought
to 5 mL by adding dichloromethane. After the addition of
1 mL ethanol, the flasks were kept aside for 5 min, then
diluted up to the mark with ethanol and absorbance was
measured at 410 nm against the reagent blank.
(III) Method C

Chemicals used were of analytical grade. The
solvents used were of the spectroscopic grade. Distilled
water was used throughout the investigation.
Zero point one molar concentration Sulphuric acid
(S.D. Fine Chem, Mumbai, India, Sp. gr. 1.84), 0.25%
bromocresol purple (S.D. Fine Chem Ltd, Mumbai,
India), 0.5 M sodium acetate (Merck Specialities Pvt
Ltd, Mumbai, India) and sodium acetate-hydrochloric
acid buffer of pH 2.4 (hydrochloric acid, Merck Specialities Pvt Ltd, Mumbai, India, Sp. gr. 1.18) were prepared
usually in water. A 1% (w/v) ethanolic KOH (S.D. Fine
Chem Ltd, Mumbai, India) was prepared in ethanol.

Varying aliquots of LMT-BCP complex (1 µg/mL,
prepared by following the procedure described in method
A) equivalent to 50-600 ng/mL with respect to LMT
were transferred into a series of 10-mL standard flasks
and the total volume was brought to 6 mL by adding
dichloromethane. To each flask, 1 mL of alcoholic KOH
was added, the content was mixed and kept aside for
5 min. Finally, the volume was made up to the mark with
ethanol and the absorbance was measured at 600 nm
against the reagent blank as reference.
In all the three methods, standard graph was
prepared by plotting the absorbance versus drug concentration, and the concentration of the unknown was read
from the calibration graph or computed from the respective regression equation derived using the absorbanceconcentration data.

(I) Standard Drug Solution

IV. Analysis of Pharmaceutical Formulations

Phramaceutical grade LMT (99.88% pure) was
procured from Cipla India Ltd, Mumbai, India, as a gift,

Lamosyn 100 and Lamosyn 25 (Sun Pharmaceuticals
Ltd, Mumbai, India) and Lametec 50 DT (Cipla India Ltd,

II. Chemicals and Reagents

426
Journal of Food and Drug Analysis, Vol. 17, No. 6, 2009

Mumbai, India) - all tablets, were used in the investigation. An amount of finely ground tablet powder equivalent
to 4 mg of LMT was accurately weighed into a 100-mL
calibrated flask, 50 mL of 0.1 M H 2SO4 was added, and
the flask was shaken for 20 min; and finally made upto the
mark with the same 0.1 M H 2SO4. The content was kept
aside for 5 min, and filtered using Whatman No. 42 filter
paper. First 10 mL portion of the filtrate was discarded
and a suitable aliquot (say 3 mL) was used for assay by
method A. The ion-pair complex (40 µg/mL in LMT)
prepared above, was diluted with dichloromethane to
obtain 3.0 µg/mL and 1.0 µg/mL solutions with respect
to LMT for assay by applying the procedures described
under method B and method C, respectively. The results
of assay were presented in Table 3.

complex into its constituents. Water present in alcohol,
however small it might be, enhances autoionisation of
ethanol thereby further facilitating the breaking of the
ion-pair complex. Under the same experimental conditions the blanks had negligible absorbance in all the three
instances. The absorbption spectra of the LMT-BCP ionpair complex, and of the undissociated and dissociated
forms of the dye are shown in the Figure 1. The possible
reaction scheme for the formation of ion-pair complex
and its breaking are shown in scheme 1 and scheme 2
respectively.
In order to establish optimum conditions necessary
for rapid and quantitative formation of coloured products with maximum stability and sensitivity, control

RESULTS AND DISCUSSION
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Figure 1. Absorption spectra of ion-pair complex and various forms
of dye. A: ion-pair complex (4.0 µg/mL LMT); B: acid form of dye
(750 ng/mL LMT); C: base form of dye (275 ng/mL LMT) and D:
blank.
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The drug LMT in its protonated form reacts
with bromocresol purple, an anionic dye, in aqueous
solution at pH 2.40 ± 0.01 to form yellow dichloromethane-extractable complex. The absorption spectra
of the extracted complex was recorded over the range
300-700 nm. The complex showed a maximum absorbance at 410 nm, which could be used as the wavelength
for determination in method A. This drug-dye ion-pair
complex was broken either in ethanol and the resulting
yellow dye was measured at 410 nm in method B or in
ethanolic KOH to give free base form of the dye which
was measured at 600 nm in method C. In method B,
the protonated ethanol, a product of autoionisation
of ethanol(21) believed to cause breaking the ion-pair
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Figure 3. Effect of pH of aqueous phase on the formation and extraction of ion-pair complex.
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Figure 2. Job’s method of equimolar solutions for the LMT-BCP
complex in dichloromethane.

I. Method Development: Optimization of Experimental
Variables
(I) Method A
(1) Effect of pH

experiments were performed by measuring the absorbance at 410 nm in method A and method B, and at 600
nm in method C by varying one and fixing the other
parameters in each case.

In order to establish the optimum pH range, 5 mL
of LMT solution in 0.1 M H 2SO 4 was diluted with 5, 10,
15, 20 and 25 mL of water before mixing with 5 mL of
the dye solution in the presence of 2 mL of 0.5 M NaOAc
and 5 mL buffer, and the effective pH of the resulting
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aqueous solution ranged from 2.35 ± 0.01 to 2.59 ± 0.01.
Figure 3 shows that a higher absorbance was observed
at pH 2.40, and the absorbance of the reagent blank was
negligible at this pH range. Above and below this pH,
the sensitivity decreases. There was no complete separation of the organic and aqueous phase at pH values
less than 2.40 due to emulsion formed between the two
layers. It was also found that a ratio of 3:1 of aqueous to
organic phases was required for efficient extraction of
the coloured species. Hence, an aqueous phase of 32 mL
which includes 15 mL of H 2O was used in all subsequent
work.

(6) Effect of Number of Extractions

(2) Effect of Sodium Acetate, BCP and Buffer Concentrations

The organic and aqueous phases were clearly separated in less than 1 min. The drug-dye ion-pair complex
was stable for more than 12 h at laboratory temperatute
(30 ± 2 º C).

Various amounts of NaOAc were added to the acidic
solution of lamotrigine to bring the pH to the optimum
value and measurements were carried out as recommended. Maximum absorbance was observed when the
volume of NaOAc was 2 mL (0.5 M) in a total volume of
32 mL. The effect of BCP concentration was investigated
by varying the volume of dye solution, and using a fixed
amount of drug. The complex formation and its extraction were unaffected in the range of 4.0 to 8.0 mL of
0.25% BCP solution. Hence, 5 mL of 0.25% BCP solution
was fixed in a total volume of 32 mL of aqueous phase.
Various amounts of buffer solution were used in the
investigation to establish its effect on the absorbance.
There was almost no influence on the absorbance up to
10 mL, but an amount less than 4 mL resulted in unsatisfactory separation of the organic phase during the
extraction. So 5 mL of buffer was used throughout the
investigation.
(3) Reaction Time
After the addition of dye, the effect of standing time
was studied in the time range 5-30 min before extraction.
After a contact time of 5 min, measured absorbance of the
complex after extraction into dichloromethane, showed
almost constant absorbance values from 5-30 min. So a
contact time of 5 min was adequate to form the complex.
(4) Effect of Shaking Time
Shaking times ranging from 30 to 60 seconds,
produced no change in absorbance, by maintaining all
other parameters constant. So a 30 sec shaking time was
fixed.
(5) Choice of Organic Solvents
In the preliminary experiments, chloroform, benzene,
carbon tetrachloride, cyclohexane, hexane were tried as
extraction solvents. None of these systems showed better
sensitivity compared to dichloromethane. Hence, dichloromethane was chosen as the solvent for extraction.

Under optimum conditions, the drug-dye complex
in the aqueous phase was extracted with three 10 mL
portions of DCM and absorbance was measured each
time. After the second extraction, the absorbance of
the organic layer was negligibly small. Hence, a single
extraction with 10 mL of DCM was selected for the
extraction because of complete recovery of the complex.
(7) Equilibration Time and Stability of the Coloured
Complexes

(8) Effect of Order of Addition of Reactants
The sequence of order of addition of the reactants
prior to extraction had small change in the absorbance
values. So the order of addition of reactants should be
in the described manner. The complexing ratio of LMT
and BCP in method A was examined by Job’s continuous
variations method (22). The concentration of the aqueous
dye and the drug was 7.81 × 10 -4 M. Six solutions
containing LMT and BCP in various molar ratios, with
a total volume of 5 mL, in addition to 15 mL H 2O, 2 mL
of 0.5 M NaOAc and 5 mL buffer solution were prepared.
The extraction was performed using 10 mL of dichloromethane and the absorbance subsequently was measured
at 410 nm. The graph of the results obtained (Figure 2)
gave a maximum at a molar ratio of X max = 0.5 which
indicated the formation of a 1:1 LMT-BCP complex. The
conditional stability constant (K f ) of the ion-association
complex was calculated from the continuous variation
data using the following equation(23):

Kf =

A / Am

 1 − A / Am  n+ 2 C M (n) n

Where A and Am are the observed maximum absorbance
and the absorbance value when all the drug present is associated, respectively. CM is the mole concentration of drug at
the maximum absorbance and n is the stoichiometry which
BCP ion associates with drug. The log Kf value was found
to be 4.730.
II. Method Validation
(I) Linearity,
Quantification

Sensitivity,

Limits

of

Detection

and

Calibration graphs were constructed from ten,
eight and eight points covering the concentration ranges
2.0-20.0 µg/mL, 150-1500 ng/mL and 50-600 ng/mL for
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different days to determine the intermediate precision
(inter-day precision) of the methods. These assays were
performed for three levels of analyte. The results of this
study are summarized in Table 2. The percentage relative
standard deviation (% RSD) values were ≤ 1.39% (intraday) and ≤ 2.01% (inter-day) indicating high precision
of the methods. The accuracy of the methods was determined by the percent mean deviation from known concentration, bias % = [(concentration found - known concentration) × 100 / known concentration]. Bias was calculated
at each concentration and these results are also presented
in Table 2. Percent relative error (% RE) values ≤ 1.33%
demonstrate the high accuracy of the proposed methods.

method A, method B and method C, respectively. Regression analysis of the Beer’s law data indicated a linear relationship between absorbance and concentration (Table 1)
which is corroborated by high values (close to unity) of
the correlations coefficients. A plot of log absorbance and
log concentration, yielded straight lines with slope equal
to 1.024, 1.023 and 1.002 for method A, method B and
method C, respectively, further establishing the linear
relation between the two variables. The calculated molar
absorptivity and Sandell sensitivity(24) values are summarized in Table 1. The limits of detection (LOD) and quantification (LOQ) were calculated using the formulae:
LOD = 3.3 S/b and LOQ = 10 S/b,
(where S is the standard deviation of blank absorbance values, and b is the slope of the calibration plot),
calculated according to the ICH guidelines (25), are also
summarized in Table 1. The high values of ε and low
values of Sandell sensitivity and LOD indicate the high
sensitivity of the proposed methods.

(III) Selectivity
A systematic study was performed to determine
the effect of matrix by analyzing the placebo blank and
synthetic mixture containing LMT. A placebo blank of
the composition: starch (10 mg), acacia (15 mg), hydroxyl
cellulose (10 mg), sodium citrate (10 mg), talc (20 mg),
magnesium stearate (15 mg) and sodium alginate (10 mg)
was obtained and its solution was prepared as described
under ‘tablets’, and then subjected to analysis. The absorbance of the placebo solution in each case was almost

(II) Precision and Accuracy
The assays described under “General Procedures”
were repeated seven times within the day to determine
the repeatability (intra-day precision) and five times on

Table 1. Sensitivity and regression parameters
Parameter
lmax (nm)
Color stability
Linear range

Method A

Method B

Method C

410

410

600

> 12 h

> 24 h

> 24 h

2.0-20 µg/mL

150-1500 ng/mL
1.433 × 10

4.212 × 105

0.0252

0.0018

0.0006

Limit of detection (LOD) (mg/mL)

0.27

0.02

0.01

Limit of quantification (LOQ) (mg/mL)

0.80

0.06

0.02

Intercept (a)

-0.0147

-0.0053

0.0030

Slope (b)

0.0415

0.5701

1.6343

Standard deviation of a (Sa)

0.0998

0.0065

0.0052

± tSa/√n

0.0713

0.0046

0.0033

Standard deviation of b (Sb)

0.0055

0.0048

0.0087

± tSb/√n

0.0039

0.0034

0.0055

1.0 × 10-3

4.3 × 10-5

2.70 × 10-5

0.9988

0.9997

0.9999

Sandell sensitivity* (µg/cm)

5

100-600 ng/mL

1.018 × 10

Molar absorptivity(ε) (L/mol/cm)

4

**

Regression equation, Y

Variance (Sa2)
Regression coefficient (r)

*Limit of determination as the weight in µg per mL of solution, which corresponds to an absorbance of A = 0.001 measured in a cuvette of
cross-sectional area 1 cm 2 and l = 1 cm.
**
Y = a + b X, where Y is the absorbance; X is concentration in µg/mL; a is intercept; b is slope; ± tSa /√n = confidence limit for intercept; ±
tSb/√n = confidence limit for slope.
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equal to the absorbance of the blank which revealed no
interference. To assess the role of the inactive ingredients on the assay of LMT, a synthetic mixture was separately prepared by adding 10 mg of LMT to the placebo
mentioned above. The drug was extracted and solution prepared as described under the general procedure for tablets. The solution after appropriate dilution
were analyzed following the recommended procedures.
The absorbance resulting from 15 µg/mL (method A),
1000 ng/mL (method B) and 400 ng/mL (method C) were
nearly the same as those obtained for pure LMT solutions
of identical concentrations. This unequivocally demonstrated the non-interference of the inactive ingredients in
the assay of LMT. Further, the slopes of the calibration
plots prepared from the synthetic mixture solutions were
about the same as those prepared from pure drug solutions.

(IV) Robustness and Ruggedness
The robustness of the methods was evaluated by
making small incremental changes in volume of H 2O/
ethanol/ethanolic KOH and contact time and the effect
of the changes was studied on the absorbance of the
coloured systems. The changes had negligible influence
on the results as revealed by small intermediate precision
values expressed as % RSD (< 1.5%).
Method ruggedness was demonstrated by having
the analysis done by four analysts, and also by a single
analyst performing analysis on four different instruments in the same laboratory. Intermediate precision
values (% RSD) in both instances were in the range
0.56-2.65% indicating acceptable ruggedness. The results
are presented in Table 3.

Table 2. Evaluation of intra-day and inter-day accuracy and precision
Method

LMT taken*

A

B

C

Intra-day accuracy and precision (n = 7)
LMT found* ± CL

% RE

% RSD

6.0

6.07 ± 0.07

1.10

1.25

12.0

11.9 ± 0.15

0.83

1.39

18.0

17.8 ± 0.11

1.1

0.64

300

302 ± 3.75

0.67

900

895 ± 8.88

0.59

1500

1480 ± 12.61

1.33

0.92

200

201 ± 1.36

0.25

400

404 ± 1.42

600

604 ± 4.14

Inter-day accuracy and precision (n = 5)
LMT found* ± CL

% RE

% RSD

6.06 ± 0.15

1.0

2.01

12.01 ± 0.23

0.08

1.56

17.96 ± 0.23

0.22

1.02

1.34

302 ± 4.94

0.66

1.32

1.07

901 ± 11.30

0.11

1.01

1498 ± 36.2

0.13

1.95

0.73

201 ± 1.97

0.50

0.79

0.97

0.38

401.1 ± 4.72

0.28

0.95

0.59

0.74

602.1 ± 7.83

0.35

1.05

% RE: Percent relative error; % RSD: relative standard deviation and CL.
Confidence limits were calculated from: CL = ± tS/√n (The tabulated value of t is 2.45 and 2.77 for six and four degrees of freedom respectively, at the 95% confidence level; S = standard deviation and n = number of measurements).
*The values are in µg/mL in method A and ng/mL in method B and method C.

Table 3. Method robustness and ruggedness expressed as intermediate precision (% RSD)
Robustness
Method

*

Ruggedness

Parameters altered

LMT taken*

Volume of H2O/Ethanol /
Ethanolic KOH**

Reaction/Breaking timeΨ

Inter-analysts
(% RSD), (n = 4)

Inter-instruments
(% RSD), (n = 4)

A

15

1.26

0.85

0.72

2.65

B

1000

0.85

1.06

0.69

1.97

C

400

0.76

0.92

0.56

2.36

The values are in µg/mL in method A and ng/mL in method B and method C.
In method A, the volume of H2O was 13, 15 and 17 mL; in method B, the volumes of ethanol added were 0.8, 1.0 and 1.2 mL and in method
C, the volumes of ethanolic KOH added were 0.8, 1.0 and 1.20 mL.
Ψ
In method A, the reaction times were 3, 5 and 7 min and in method B and method C the breaking times were 3, 5 and 7 min.
**
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Table 4. Results of analysis of tablets by the proposed methods and statistical comparison of the results with the reference method
Found* (Percent of label claim ± SD)

Tablet brand nameψ

Nominal amount
(mg/tablet)

Reference method

Lamosyn-100a

100

98.48 ± 0.65

Lamosyn-25a

25

b

Lametec-50 DT

50

100.4 ± 0.56

102.3 ± 0.74

Method A

Method B

Method C

99.12 ± 0.86

98.76 ± 0.54

98.14 ± 0.45

t = 1.34

t = 0.74

t = 0.98

F = 1.75

F = 1.45

F = 2.09

100.8 ± 0.92

101.2 ± 0.72

100.1 ± 0.36

t = 0.85

t = 1.98

t = 1.03

F = 2.70

F = 1.65

F = 2.42

102.7 ± 1.04

101.7 ± 0.86

101.1 ± 0.53

t = 0.71

t = 1.18

t = 2.99

F = 1.98

F = 1.35

F = 1.95

*Mean value of 5 determinations.
(Tabulated t-value at the 95 % confidence level and for four degrees of freedom is 2.77).
(Tabulated F-value at the 95 % confidence level and for four degrees of freedom is 6.39).
ψ
Marketed by: aSun pharmaceuticals; bCipla India Ltd, Mumbai.

(V) Application
The proposed methods were applied for the quantification of LMT in commercial tablets. The results were
compared with these obtained by a published method (19).
The method consisted of the measurement of the absorbance of the tablet extract in 0.1 M NaOH at 305 nm.
Statistical analysis of the results did not detect any
significant difference between the performance of the
proposed methods and reference method with respect
to accuracy and precision as revealed by the Student’s
t-value and variance ratio F-value (26). The results of assay
are given in Table 4.
(VI) Recovery Study
To further assess the accuracy of the methods,
recovery experiments were performed by applying the
standard-addition technique. The recovery was assessed
by determining the agreement between the measured
standard concentration and added known concentration to the sample. The test was done by spiking the preanalysed tablet powder with pure LMT at three different
levels (50, 100 and 150% of the content present in the
tablet powder (taken) and the total was found by the
proposed methods. Each test was repeated three times.
In all the cases, the recovery percentage values ranged
between 96.36 and 103.7 with standard deviation in the
range 0.42-1.25%. Closeness of the results to 100%
showed the fairly good accuracy of the methods. The
results are shown in Table 5.

CONCLUSIONS
The presented work describes validated spectrophotometric methods for the determination of lamotrigine
in bulk drug and in tablets. The proposed methods are
highly sensitive and are 10-300-fold more sensitive than
the only visible spectrophotometric method reported.
The sensitivity offered by the proposed methods
surpasses even that of the existing HPLC methods in
terms of linear range and quantification limits. The
methods are quite selective as the drug contains basic
moiety which preferentially interacts with bromocresol
purple, and the drug-dye ion-pair is extracted into the
organic solvent before measurement. The methods are
free from interferences from the common excipients and
additives. The statistical parameters and the recovery
data reveal good accuracy and precision of the methods.
Hence, methods can be used in routine analysis of drug
in quality control laboratories.
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